Response by Jones et al to Letter Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease"

Affiliations

¹ From Duke Clinical Research Institute and Department of Medicine, Duke University Medical Center, Durham, NC (W.S.J., M.R.P.); and University of Colorado School of Medicine and CPC Clinical Research, Aurora (W.R.H.).

Comment

W Schuyler Jones et al. Circulation. 2017.

. 2017 Jun 6;135(23):e1109-e1110.

doi: 10.1161/CIRCULATIONAHA.117.028199.

¹ From Duke Clinical Research Institute and Department of Medicine, Duke University Medical Center, Durham, NC (W.S.J., M.R.P.); and University of Colorado School of Medicine and CPC Clinical Research, Aurora (W.R.H.).

No abstract available

Comment on

Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.
Jones WS, Baumgartner I, Hiatt WR, Heizer G, Conte MS, White CJ, Berger JS, Held P, Katona BG, Mahaffey KW, Norgren L, Blomster J, Millegård M, Reist C, Patel MR, Fowkes FG; International Steering Committee and Investigators of the EUCLID Trial. Jones WS, et al. Circulation. 2017 Jan 17;135(3):241-250. doi: 10.1161/CIRCULATIONAHA.116.025880. Epub 2016 Nov 13. Circulation. 2017. PMID: 27840336 Clinical Trial.
Letter by Moris et al Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease".
Moris D, Patelis N, Kakkos S. Moris D, et al. Circulation. 2017 Jun 6;135(23):e1105-e1106. doi: 10.1161/CIRCULATIONAHA.116.026865. Circulation. 2017. PMID: 28584034 No abstract available.
Letter by Siasos et al Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease".
Siasos G, Moris D, Tousoulis D. Siasos G, et al. Circulation. 2017 Jun 6;135(23):e1107-e1108. doi: 10.1161/CIRCULATIONAHA.116.026927. Circulation. 2017. PMID: 28584035 No abstract available.